Safety concerns with the long-term management of osteoporosis

Expert Opinion on Drug Safety

Volumn 12, Issue 4, 2013, Pages 507-522

  Reginster, Jean Yves ^a   Pelousse, Franz ^b   Bruyère, Olivier ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b Centre Hospitalier Regional de La Citadelle   (Belgium)

Author keywords

Bisphosphonates; Calcitonin; Denosumab; Long term safety; Osteoporosis; Selective estrogen receptor modulators; Strontium ranelate

Indexed keywords

ALENDRONIC ACID; BAZEDOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; DENOSUMAB; ETIDRONIC ACID; IBANDRONIC ACID; LASOFOXIFENE; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; ZOLEDRONIC ACID;

ADVERSE DRUG REACTION; ANGIONEUROTIC EDEMA; BONE DENSITY; BREAST CANCER; CALCIUM BLOOD LEVEL; CANCER RISK; CELLULITIS; COLORECTAL CANCER; DRESS SYNDROME; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; ERYSIPELAS; ESOPHAGUS CANCER; FEMUR FRACTURE; FEMUR SUBTROCHANTERIC FRACTURE; FRACTURE; HEART ATRIUM FIBRILLATION; HIP FRACTURE; HOT FLUSH; HUMAN; HYPOCALCEMIA; JAW OSTEONECROSIS; LEG CRAMP; LUNG EMBOLISM; PERIPHERAL EDEMA; POSTMENOPAUSE OSTEOPOROSIS; PRURITUS; REVIEW; SKIN ALLERGY; SKIN DISEASE; SKIN INFECTION; SKIN ULCER; SPINE FRACTURE; STEVENS JOHNSON SYNDROME; STOMACH CANCER; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UTERINE POLYP; VAGINA CANDIDIASIS; VENOUS THROMBOEMBOLISM;

ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY CONSERVATION AGENTS; CALCITONIN; DIPHOSPHONATES; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; THIOPHENES;

EID: 84879369335     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2013.793669     Document Type: Review

References (96)

1. Harvey N, Dennison E, Cooper C. Osteoporosis: impact on health and economics. Nat Rev Rheumatol 2010;6:99-105
2. Kaufman JM, Reginster JY, Boonen S, et al. Treatment of osteoporosis in men. Bone 2013;53:134-44
3. Kanis JA, McCloskey EV, Johansson H, et al. Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2013;24:23-57
4. Gallacher SJ, Dixon T. Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review. Calcif Tissue Int 2010;87:469-84
5. Silverman SL, Cummings SR, Watts NB. Recommendations for the clinical evaluation of agents for treatment of osteoporosis: consensus of an expert panel representing the American Society for Bone and Mineral Research (ASBMR), the International Society for Clinical Densitometry (ISCD), and the National Osteoporosis Foundation (NOF). J Bone Miner Res 2008;23:159-65
6. Cooper C, Reginster JY, Cortet B, et al. Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). Curr Med Res Opin 2012;28:475-91
7. Chesnut CH III, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000;109:267-76
8. European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). European Medicines Agency recommends limiting long-term use of calcitonin medicines. Press release EMA/CHMP/483874/2012. 2012.Available from: http://www.ema. europa.eu/docs/en-GB/document-library/Press-release/2012/07/ WC500130122. pdf [Last accessed 31 January 2013]
9. Heep M. Calcitonin use and risk of malignancy: a meta-analysis of 17 RCTs in patients with osteoporosis [abstract 1234]. Abstract presented at the American Society for Bone and Mineral Research (ASBMR) 2012 Annual Meeting; Minneapolis, Minnesota, USA; 2012
10. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial. JAMA 1999;282:637-45 (Pubitemid 29384151)
11. Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008;23:1923-34
12. Cummings SR, Ensrud K, Delmas PD, et al. PEARL Study Investigators. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 2010;362:686-96
13. Delmas PD, Ensrud KE, Adachi JD, et al. Multiple Outcomes of Raloxifene Evaluation Investigators. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002;87:3609-17 (Pubitemid 34879503)
14. Martino S, Cauley JA, Barrett-Connor E, et al. CORE Investigators. Continuing Outcomes Relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004;96:1751-61 (Pubitemid 39654569)
15. Siris ES, Harris ST, Eastell R, et al. Continuing Outcomes Relevant to Evista (CORE) Investigators. Skeletal effects of raloxifene after 8 years: results from the Continuing Outcomes Relevant to Evista (CORE) study. J Bone Miner Res 2005;20:1514-24 (Pubitemid 41243540)
16. de Villiers TJ, Chines AA, Palacios S, et al. Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporos Int 2011;22:567-76
17. Silverman SL, Chines AA, Kendler DL, et al. Bazedoxifene Study Group. Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporos Int 2012;23:351-63
18. Komm BA, Chines AA. The evolving role of third-generation selective estrogen-receptor modulators in the management of postmenopausal osteoporosis. Ther Adv Musculoskel Dis 2012;4:21-34
19. Layton D, Clarke A, Wilton LV, Shakir SA. Safety profile of raloxifene as used in general practice in England: results of a prescription-event monitoring study. Osteoporos Int 2005;16:490-500
20. Breart G, Cooper C, Meyer O, et al. Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database. Osteoporos Int 2010;21:1181-7
21. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-37 (Pubitemid 44050394)
22. Vestergaard P, Schwartz K, Pinholt EM, et al. Use of bisphosphonates and raloxifene and risk of deep venous thromboembolism and pulmonary embolism. Osteoporos Int 2010;21:1591-7
23. Lamberg AL, Horvath-Puho E, Christensen S, Sorensen HT. Use of oral bisphosphonates and risk of venous thromboembolism: a population-based case-control study. Osteoporos Int 2010;21:1911-17
24. Black DM, Thompson DE, Bauer DC, et al. Fracture Intervention Trial. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000;85:4118-24 (Pubitemid 32055362)
25. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83-91 (Pubitemid 30099515)
26. Chesnut CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9 (Pubitemid 41094364)
27. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22 (Pubitemid 46698462)
28. Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2012;27:243-54
29. Schwartz AV, Schafer AL, Grey A, et al. Effects of antiresorptive therapies on glucose metabolism: results from the FIT, HORIZON-PFT and FREEDOM trials. J Bone Miner Res 2013; Epub ahead of print
30. Rizzoli R, Reginster JY, Boonen S, et al. Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int 2011;89:91-104
31. Ettinger B, Burr DB, Ritchie RO. Proposed pathogenesis for atypical femoral fractures: lessons from material research. Bone 2013; In press
32. Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008;358:1304-6 (Pubitemid 351439247)
33. Abrahamsen B, Eiken P, Eastell R. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based National Cohort Analysis. J Clin Endocrinol Metab 2010;95:5258-65
34. Vestergaard P, Schwartz F, Rejnmark L, Mosekilde L. Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene. Osteoporos Int 2011;22:993-1001
35. Erviti J, Alonso A, Oliva B, et al. Oral bisphosphonates are associated with increased risk of subtrochanteric and diaphyseal fractures in elderly women: a nested case-control study. BMJ Open 2013;3(1):e002091
36. Schilcher J, Michaëlsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011;364:1728-37
37. Rizzoli R, Akesson K, Bouxsein M, et al. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int 2011;22:373-90
38. Gedmintas L, Solomon DH, Kim SC. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res 2013; Epub ahead of print
39. Ahlman MA, Rissing MS, Gordon L. Case review: Evolution of bisphosphonate related atypical fracture retrospectively observed with DXA scanning. J Bone Miner Res 2012;27:496-8
40. Thompson RN, Phillips JR, McCauley SH, et al. Atypical femoral fractures and bisphosphonate treatment: experience in two large United Kingdom teaching hospitals. J Bone Joint Surg Br 2012;94:385-90
41. Gomberg SJ, Wustrack RL, Napoli N, et al. Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy. J Clin Endocrinol Metab 2011;96:1627-32
42. Carvalho NN, Voss LA, Almeida MO, et al. Atypical femoral fractures during prolonged use of bisphosphonates: short-term responses to strontium ranelate and teriparatide. J Clin Endocrinol Metab 2011;96:2675-80
43. Negri AL, Spivacow FR. Healing of subtrochanteric atypical fractures after strontium ranelate treatment. Clin Cases Miner Bone Metab 2012;9:166-9
44. Rizzoli R, Burlet N, Cahall D, et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 2008;42:841-7
45. Chiu WY, Lee JJ, Tsai KS. Atypical femoral fractures shortly after osteonecrosis of the jaw in a postmenopausal woman taking alendronate for osteoporosis. J Clin Endocrinol Metab 2013; Epub ahead of print
46. Vestergaard P, Schwartz K, Rejnmark L, et al. Oral bisphosphonate use increases the risk for inflammatory jaw disease: a cohort study. J Oral Maxillofac Surg 2012;70:821-9
47. Filleul O, Crompot E, Saussez S. Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases. J Cancer Res Clin Oncol 2010;136:1117-24
48. Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation. N Engl J Med 2007;356:1895-6
49. Loke YK, Jeevanantham V, Singh S. Bisphosphonates and atrial fibrillation: systematic review and meta-analysis. Drug Saf 2009;32:219-28
50. Howard PA, Barnes BJ, Vacek JL, et al. Impact of bisphosphonates on the risk of atrial fibrillation. Am J Cardiovasc Drugs 2010;10:359-67
51. Vestergaard P, Schwartz K, Pinholt EM, et al. Risk of atrial fibrillation associated with use of bisphosphonates and other drugs against osteoporosis: a cohort study. Calcif Tissue Int 2010;86:335-42
52. Heckbert SR, Li G, Cummings SR, et al. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 2008;168:826-31 (Pubitemid 351649266)
53. Pazianas M, Compston J, Huang C. Atrial fibrillation and bisphosphonate therapy. J Bone Miner Res 2010;25:2-10
54. Body JJ, Bergmann P, Boonen S, et al. Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications. Osteoporos Int 2012;23(Suppl 1):S1-23
55. Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009;360:89-90
56. Abrahamsen B, Pazianas M, Eiken P, et al. Esophageal and gastric cancer incidence and mortality in alendronate users. J Bone Miner Res 2012;27:679-86
57. Vestergaard P. Occurrence of gastrointestinal cancer in users of bisphosphonates and other antiresorptive drugs against osteoporosis. Calcif Tissue Int 2011;89:434-41
58. Green J, Czanner G, Reeves G, et al. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ 2010;341:c4444
59. Cardwell CR, Abnet CC, Cantwell MM, Murray LJ. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 2010;304:657-63
60. Vinogradova Y, Coupland C, Hippisley-Cox J. Exposure to bisphosphonates and risk of gastrointestinal cancers: series of nested case-control studies with QResearch and CPRD data. BMJ 2013;346:f114
61. Thosani N, Thosani SN, Kumar S, et al. Reduced risk of colorectal cancer with use of oral bisphosphonates: a systematic review and meta-analysis. J Clin Oncol 2013;31:623-30
62. Winter MC, Holen I, Coleman RE. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 2008;34:453-75
63. Gnant M. Bisphosphonates in the prevention of disease recurrence: current results and ongoing trials. Curr Cancer Drug Targets 2009;9:824-33
64. Vestergaard P, Fischer L, Mele M, et al. Use of bisphosphonates and risk of breast cancer. Calcif Tissue Int 2011;88:255-62
65. Dunn RL, Bird ML, Conway SE, Stratton MA. Use of bisphosphonates in older adults: how long is long enough? Consult Pharm 2013;28:39-57
66. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-Term Extension (FLEX): a randomized trial. JAMA 2006;296:2927-38 (Pubitemid 46021497)
67. Whitaker M, Guo J, Kehoe T, Benson G. Bisphosphonates for osteoporosis-where do we go from here? N Engl J Med 2012;366:2048-51
68. Mellstrom DD, Sorensen OH, Goemaere S, et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004;75:462-8 (Pubitemid 40174503)
69. Black DM, Bauer DC, Schwartz AV, et al. Continuing bisphosphonate treatment for osteoporosis-for whom and for how long? N Engl J Med 2012;366:2051-3
70. Brown JP, Roux C, Torring O, et al. Discontinuation of denosumab and associated fracture incidence: analysis from the FREEDOM trial. J Bone Miner Res 2012; Epub ahead of print
71. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-65
72. Papapoulos S, Chapurlat R, Libanati C, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res 2012;27:694-701
73. Prolia (denosumab) [package insert]. Amgen, Inc., Thousand Oaks, CA; 2011
74. Watts NB, Roux C, Modlin JF, et al. Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association? Osteoporos Int 2012;23:327-37
75. McClung MR, Lewiecki EM, Geller ML, et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int 2013;24:227-35
76. Anastasilakis AD, Toulis KA, Goulis DG, et al. Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis. Horm Metab Res 2009;41:721-9
77. Toulis KA, Anastasilakis AD. Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab. Osteoporos Int 2010;21:1963-4
78. Taylor KH, Middlefell LS, Mizen KD. Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J Oral Maxillofac Surg 2010;48:221-3
79. Diz P, López-Cedr-un JL, Arenaz J, Scully C. Denosumab-related osteonecrosis of the jaw. J Am Dent Assoc 2012;143:981-4
80. Paparodis R, Buehring B, Pelley E, Binkley N. A case of an unusual subtrochanteric fracture in a patient receiving denosumab. Endocr Pract 2013; Epub ahead of print
81. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-68 (Pubitemid 38133766)
82. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90:2816-22 (Pubitemid 40686329)
83. Reginster JY, Felsenberg D, Boonen S, et al. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum 2008;58:1687-95 (Pubitemid 351847521)
84. Reginster JY, Kaufman JM, Goemaere S, et al. Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis. Osteoporos Int 2012;23:1115-22
85. European Medicines Agency (2009) Strontium ranelate. Summary of product characteristics. Available from: http://www.emea.europa.eu [Last accessed 31 January 2013]
86. Osborne V, Layton D, Perrio M, et al. Incidence of venous thromboembolism in users of strontium ranelate: an analysis of data from a prescription-event monitoring study in England. Drug Saf 2010;33:579-59
87. Audran M, Jakob F, Palacios S, et al. A large prospective European cohort study of patients treated with strontium ranelate and followed up over 3 years. Rheum Int 2013; Epub ahead of print
88. Musette P, Kaufman JM, Rizzoli R, et al. Cutaneous side effects of antiosteoporosis treatments. Ther Adv Muscul Dis 2011;3:31-41
89. Cacoub P, Descamps V, Meyer O, et al. Drug rash with eosinophilia and systemic symptoms (DRESS) in patients receiving strontium ranelate. Osteoporos Int 2013; Epub ahead of print
90. European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). European Medicines Agency confirms positive benefit-risk balance of Protelos/Osseor, but recommends new contraindications and revised warnings. Press release EMA/CHMP/185175/2012. 2012. Available from: http://www.ema.europa. eu/docs/en-GB/document-library/Press-release/2012/03/WC500124206. pdf [Last accessed 5 February 2013]
91. Bolland MJ, Grey AB, Gamble GD, Reid IR. Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab 2010;95:1174-81
92. Seeman E, Compston J, Adachi J, et al. Non-compliance: the Achilles' heel of anti-fracture efficacy. Osteoporosis Int 2007;18:711-19 (Pubitemid 46684777)
93. McHorney CA, Schousboe JT, Cline RR, Weiss TW. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates. Curr Med Res Opin 2007;23:3137-52
94. Ott SM. What is the optimal duration of bisphosphonate therapy? Cleve Clin J Med 2011;78:619-30
95. Dawson-Hughes B, Mithal A, Bonjour JP, et al. IOF position statement: vitamin D recommendations for older adults. Osteoporos Int 2010;21:1151-4
96. Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004;35:375-82 (Pubitemid 38953182)